How many weeks before a competition should I start using Drostanolone Enanthate for contest prep?

Most competitive athletes introduce drostanolone enanthate 12 to 16 weeks before their show date. The enanthate ester takes approximately 10–14 days to reach stable serum levels, so an earlier start gives the compound time to establish a consistent androgenic baseline before the critical final four-week conditioning phase begins. Starting too late limits the hardening effect and leaves insufficient time for dosage adjustments.

What weekly dose of Drostanolone Enanthate do experienced contest competitors typically use during peak week?

Practitioner-reviewed contest-prep documentation consistently places the working range at 300–400mg per week during the final preparation phase, split into two equal injections. Some advanced athletes hold at 400mg from week eight onward, while others taper to 300mg inside the final two weeks to manage water retention. Individual response, total stack composition, and event category all influence the final number.

How does contest-phase dosing of Drostanolone Enanthate differ from a standard bodybuilding cycle?

Contest-phase dosing emphasises stability and incremental adjustment over maximising total weekly androgen load. Dose changes during prep are made in 50mg steps and evaluated over 7–10 days before further adjustment. Off-season protocols often prioritise mass accumulation with higher compound totals; contest-prep prioritises predictability so body composition readings remain interpretable and week-to-week changes can be attributed to specific variables.

Can Nassa Labs Drostanolone Enanthate 200mg/ml be drawn accurately with an insulin syringe for smaller contest-prep doses?

Standard insulin syringes (1ml, 100-unit scale) are not recommended for drawing viscous oil-based injectables like this formulation. Use a 21–23 gauge draw needle to fill the syringe, then switch to a 23–25 gauge injection needle for intramuscular administration. For 150mg doses, draw 0.75ml; for 200mg, draw 1.0ml — volume calculations are straightforward at 200mg/ml. Always confirm the draw volume before switching needles.

How should the Nassa Labs 10ml vial be stored after the first puncture?

After first use, store the vial at room temperature (15–25°C) away from direct light and heat sources — refrigeration is not required for oil-based injectables and can increase viscosity, making accurate draws more difficult. Use a clean, sterile needle for every draw to prevent microbiological contamination of the remaining oil. The vial should be discarded within 28 days of first puncture in line with standard multi-dose vial handling practice.

Competition Proven

Nassa Labs

Drostanolone Enanthate 200mg/ml 10ml Vial by Nassa Labs

Name: Drostanolone Enanthate 200mg/ml 10ml Vial by Nassa Labs
Brand: Nassa Labs
SKU: INJ-DROE-NAS-200-011
Price: 54.00 EUR
Availability: InStock

Nassa Labs Drostanolone Enanthate 200mg/ml is a long-acting injectable androgenic agent specifically structured for athletes who require stable androgen levels and precise dose control throughout the final weeks of contest preparation. At 200mg per millilitre, each 10ml vial delivers a full competition-prep supply with dosing flexibility that suits both entry-level and advanced pre-show protocols. Potency is confirmed at finished-product release via HPLC quantification and LAL endotoxin screening — two independent checkpoints applied before any vial reaches distribution.

€54.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Sustained androgenic output across the full contest-prep calendar with twice-weekly dosing
HPLC-verified 200mg/ml concentration enables exact weekly dose calculations during prep
Promotes subcutaneous water clearance and enhanced muscle density appearance in the final prep weeks
Non-aromatising structure eliminates oestrogen-related blurring that interferes with peak-week conditioning
SHBG displacement raises free androgen fraction, amplifying androgenic signalling without increasing total dose
Long release window allows stable blood-level management without frequent injection disruption to training schedules
LAL endotoxin-screened batches reduce injection-site inflammation risk during high-frequency contest prep

Phase	Weekly Dose	Injection Schedule	Note
Early Contest Prep (Weeks 16–9)	200–300mg	2× per week (equal splits)	Establish stable serum baseline; assess initial hardening response before adjusting upward
Peak Prep (Weeks 8–5)	300–400mg	2× per week (equal splits)	Primary conditioning window; evaluate body composition weekly before dose increments of 50mg
Final Phase / Peak Week (Weeks 4–1)	300–400mg (hold or step down)	2× per week	Maintain established dose or reduce to 300mg if water retention signals appear; last injection 5–7 days before show
Post-Contest / PCT Bridge	Taper or cease	As advised by supervising practitioner	Allow 14 days after last enanthate injection before initiating PCT agents to account for extended clearance

Key takeaways

Start your Drostanolone Enanthate prep 12–16 weeks out for stable serum levels.
Adjust contest-phase doses in 50mg increments, not large blocks.
Target 300–400mg per week across two equal injections during peak prep.
Confirm each draw volume against the HPLC-verified 200mg/ml concentration.
Discard open vials within 28 days and store away from direct light.

Drostanolone Enanthate as a Contest-Phase Compound

Drostanolone Enanthate is a 2α-methylated dihydrotestosterone derivative formulated with the enanthate ester, producing a sustained-release androgenic compound whose stable serum profile makes it particularly suited to the structured, week-by-week dose management that competition preparation demands. Competitive bodybuilders choose drostanolone enanthate over shorter-ester variants during longer prep windows — typically 12 to 16 weeks out — because the enanthate ester allows twice-weekly scheduling without the injection frequency burden that comes with propionate-based protocols requiring every-other-day administration. Nassa Labs supplies this compound at 200mg/ml across a 10ml vial, providing 2000mg total active substance per unit.

How Contest Dosing Differs From Off-Season Use

Contest dosing follows a different logic than off-season or maintenance dosing. Where an off-season protocol may prioritise peak androgen load, a competition-phase approach prioritises precision: each weekly dose must remain predictable in its androgenic output so the athlete can assess body composition changes week by week and adjust calories, conditioning work, and compound doses in a controlled manner. At the contest-preparation stage, most experienced athletes run drostanolone enanthate at 300–400mg per week, split across two equal injections, as reported across practitioner-reviewed contest-prep frameworks and athlete case documentation. This range delivers meaningful androgenic hardening effects — characterised by enhanced myofibrillar density appearance, accelerated subcutaneous water clearance, and a measurable increase in free androgen fraction through SHBG displacement — without the dose accumulation risk that higher weekly totals introduce when contest day is 8–12 weeks away.

Compared to higher-dose off-season androgen programmes, contest-phase drostanolone enanthate cycles operate on tighter weekly targets, with adjustments made in 50mg increments rather than large block changes. Nassa Labs' HPLC-verified concentration of 200mg/ml means each adjustment in draw volume translates directly to a known, analytically confirmed milligram change — not an estimate based on a nominal label.

Nassa Labs Quality Position for Contest Athletes

Nassa Labs subjects each production batch of this vial to two sequential release-gate tests: HPLC potency quantification against a certified drostanolone enanthate reference standard, and LAL endotoxin screening for sterility assurance. For contest athletes whose prep timelines are non-negotiable, these checks ensure that the compound reaching the vial matches the dose structure the athlete built their final weeks around. Batch-specific certificates are held within Nassa Labs' traceability register and are accessible through authorised distribution channels.

Usage

Define your show date first, then count back 12–16 weeks to set your start date — this window gives the enanthate ester adequate time to establish stable serum concentrations before peak conditioning begins.
Draw your dose using a 21–23 gauge needle from the Nassa Labs vial; at 200mg/ml, 1.0ml delivers 200mg and 1.5ml delivers 300mg — confirm your draw volume against the HPLC-verified label figure before every injection.
Switch to a 23–25 gauge needle for intramuscular injection into the glute, quad, or deltoid; rotate injection sites across your twice-weekly schedule to prevent depot accumulation at a single site.
Log each injection with date, dose, body weight, and subjective conditioning notes — this record allows you to attribute changes to specific dose adjustments rather than guessing during the evaluation window.
Reassess your dose every 7–10 days using objective markers (skinfold calipers, progress photographs under consistent lighting); make adjustments in 50mg weekly increments only — larger changes make individual variable assessment impossible during contest prep.
Schedule your last injection 5–7 days before show day to allow some decline from peak serum levels; plan PCT initiation approximately 14 days after your final injection to account for the enanthate ester's extended clearance timeline.

Warnings

Contraindications: Not for use by women (androgenic virilisation risk is high with drostanolone at contest-prep doses), individuals under 21, or anyone with known or suspected androgen-sensitive malignancy. Pre-existing cardiovascular disease, hepatic impairment, or haematological disorders require medical clearance before use.

Side Effects: Androgenic effects including accelerated scalp hair recession in genetically predisposed individuals, acne on the back and shoulders, and increased sebum production are the most commonly reported. Lipid profile disruption — specifically suppression of HDL cholesterol — is documented across androgenic cycles at contest-prep doses and represents a clinically relevant cardiovascular risk factor.

Monitoring: Track HDL/LDL ratio, haematocrit, and blood pressure at baseline, mid-cycle, and post-cycle. Liver enzyme panels (ALT, AST) should be checked mid-cycle. Endogenous testosterone suppression is expected; LH and FSH monitoring confirms the degree of HPG axis suppression at cycle end.

PCT: Endogenous testosterone recovery requires structured post-cycle therapy. Given the enanthate ester's extended clearance profile, begin PCT no earlier than 14 days after the final injection. Standard protocols combine a SERM (clomiphene or tamoxifen) across 4–6 weeks; HCG pre-PCT may be considered if the cycle extended beyond 12 weeks.

Frequently asked questions

How many weeks before a competition should I start using Drostanolone Enanthate for contest prep?: Most competitive athletes introduce drostanolone enanthate 12 to 16 weeks before their show date. The enanthate ester takes approximately 10–14 days to reach stable serum levels, so an earlier start gives the compound time to establish a consistent androgenic baseline before the critical final four-week conditioning phase begins. Starting too late limits the hardening effect and leaves insufficient time for dosage adjustments.
What weekly dose of Drostanolone Enanthate do experienced contest competitors typically use during peak week?: Practitioner-reviewed contest-prep documentation consistently places the working range at 300–400mg per week during the final preparation phase, split into two equal injections. Some advanced athletes hold at 400mg from week eight onward, while others taper to 300mg inside the final two weeks to manage water retention. Individual response, total stack composition, and event category all influence the final number.
How does contest-phase dosing of Drostanolone Enanthate differ from a standard bodybuilding cycle?: Contest-phase dosing emphasises stability and incremental adjustment over maximising total weekly androgen load. Dose changes during prep are made in 50mg steps and evaluated over 7–10 days before further adjustment. Off-season protocols often prioritise mass accumulation with higher compound totals; contest-prep prioritises predictability so body composition readings remain interpretable and week-to-week changes can be attributed to specific variables.
Can Nassa Labs Drostanolone Enanthate 200mg/ml be drawn accurately with an insulin syringe for smaller contest-prep doses?: Standard insulin syringes (1ml, 100-unit scale) are not recommended for drawing viscous oil-based injectables like this formulation. Use a 21–23 gauge draw needle to fill the syringe, then switch to a 23–25 gauge injection needle for intramuscular administration. For 150mg doses, draw 0.75ml; for 200mg, draw 1.0ml — volume calculations are straightforward at 200mg/ml. Always confirm the draw volume before switching needles.
How should the Nassa Labs 10ml vial be stored after the first puncture?: After first use, store the vial at room temperature (15–25°C) away from direct light and heat sources — refrigeration is not required for oil-based injectables and can increase viscosity, making accurate draws more difficult. Use a clean, sterile needle for every draw to prevent microbiological contamination of the remaining oil. The vial should be discarded within 28 days of first puncture in line with standard multi-dose vial handling practice.

Manufacturer

Release-gate architecture — rather than distributed QC checkpoints — defines how Nassa Labs applies analytical testing to its Drostanolone Enanthate 200mg/ml vial: two formally separated tests, HPLC content quantification against a certified drostanolone enanthate reference standard and LAL endotoxin screening, must both return passing results before a batch is cleared for any outbound movement. Neither test is treated as subordinate to the other, and neither is conducted on a sample pulled after distribution has already begun. This matters specifically for contest-prep athletes because a dose structure built around a 200mg/ml figure that is analytically confirmed — not carried over from a shared injectable template — remains actionable week over week without recalculation or margin guessing. Lot-specific certificates generated from these two tests are catalogued within Nassa Labs' traceability register and are retrievable by authorised distributors at the point of order verification, providing a documentary link between the vial in hand and the analytical record that underpins its label.

Product details

Brand	Nassa Labs
Active ingredient	drostanolone enanthate
Also known as	Masteron Enanthate, Drostanolone Enanthat, Drostanolonee Enanthate, Nassa Labs Masteron Enanthate
Strength	200 mg
Form	Vial
Pack size	1 piece
Item number	INJ-DROE-NAS-200-011

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

High Concentration

Etho-Masteron 200mg/ml 10ml Vial by Beligas Pharmaceuticals

Etho-Masteron by Beligas Pharmaceuticals is a high-concentration injectable Drostanolone Enanthate solution, dosed at 200mg/ml in a 10ml vial, engineered to integrate cleanly into structured, periodized cycle protocols where sustained androgenic support is the primary objective. The extended-release enanthate ester makes it particularly well-suited to modern cutting and recomposition blueprints that demand stable hormone levels over multi-week blocks without frequent injection windows. Batch release is governed by HPLC chromatographic quantification against certified reference standards; sterility is confirmed via LAL endotoxin assay — both conducted under GMP-compliant production conditions at Beligas Pharmaceuticals.

€54.00

Masten-200 200mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Masten-200 200mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Masten-200 is a long-chain ester injectable delivering Drostanolone Enanthate at 200 mg/ml across ten single-dose glass ampoules, distinguished by its extended pharmacokinetic profile — a half-life of approximately 10–11 days that enables stable plasma concentrations between infrequent administrations. The enanthate ester slows enzymatic cleavage of the parent hormone, sustaining active Drostanolone release across a broad time window rather than producing the sharp peak-and-trough pattern of shorter ester variants. Each batch undergoes HPLC-verified potency confirmation and LAL endotoxin testing; sterile fill integrity is independently validated before release by BM Pharmaceuticals.

€55.00

Brand Quality

Masteron 200 200mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma Masteron 200 is an oil-based injectable delivering Drostanolone Enanthate at 200 mg/ml in a 10 ml vial, formulated specifically to support structured cruise-and-blast programming where androgenic density must shift between maintenance and growth phases without changing compounds. The long-acting enanthate ester sustains active hormone levels across the full blast window and remains pharmacokinetically compatible during reduced-dose cruise intervals. Each production batch of Masteron 200 is manufactured inside a GMP-certified facility; finished vials are HPLC-quantified against a certified Drostanolone reference standard and LAL-tested for endotoxin clearance before batch release.

€48.00

Pro Choice

Drostargos 200mg/ml 10ml Vial by Driada Medical

Drostargos is a long-acting injectable androgen from Driada Medical, delivering 200 mg of Drostanolone Enanthate per millilitre across a 10 ml multi-dose vial — formulated specifically to serve men over 40 pursuing hormone optimisation and anti-aging body-composition goals alongside or adjacent to testosterone replacement therapy. Its extended-release enanthate ester sustains stable androgenic activity across the week, making twice-weekly administration practical without sharp hormonal fluctuations that complicate quality-of-life management in older users. HPLC quantification of the active content and LAL endotoxin screening are completed at GMP Standard batch release; the resulting analytical certificate travels with each vial lot.

€56.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00